History

Established in July 1998 by its president Stéphane Legastelois, Indicia Biotechnology has in its years of existence successfully transitioned from the status of a start-up to that of a SME.

 

At its inception, the company focused on the development of custom-designed latex-based microparticle laboratory reagents.

The company was thus able to acquire a specific know-how, since well acknowledged, in the processes related to binding of biological analytes on solid substrates (microparticles, microplates, membrane).

 

Over the years, the company has built and enhanced its business model by optimally positioning itself so as to engage in providing R&D service capabilities targeted at bio-industrial companies favourable towards partially or entirely outsourcing their projects.

• 2001: ANVAR participates in the financing of an innovation project
• 2005: Approval “Credit impôt recherche” by the Ministry of Education and Research (renewed in 2008)
• 2006: ISO 9001: 2000 certification
• 2007: Expansion and renovation of premises
• 2008: Acquisition of a production unit (Axcell Biotechnology - created in 1993 – near Lyon) and creation of its subsidiary Indicia Production
• 2009: Beginning of Gliadys project, a collaborative project based on therapeutic antibodies against different glioma forms.
• 2010: ISO 13485:2004 certification for  in vitro diagnostic test
• 2010: Housing of a new ultrasensitive biomarker quantification plateform (Erenna system from Singulex®) and beginning of Femtokine project whose objective is to develop novel biomarkers for the diagnosis and monitoring of Crohn’s Disease. 
• 2011: December 2011, by signing an agreement with the French company Proteus, Indicia Biotechnology has acquired the rights to exploit Immuno'line ™, a full range of services and patented technologies dedicated to Risk Assessment Immunogenicity.

 Indicia is a member of cluster LyonBiopôle and LyonBioTech.

 

(See also our news page)